Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1119 Results

Title
Intervention Indication Therapeutic Area Year Actions
Zanidatamab for treating advanced or metastatic HER2-positive biliary tract cancer in adults Zanidatamab (ZW-25) Biliary tract cancer Gastrointestinal Cancer 2023 View  |  Download
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zamtocabtagene autoleucel for relapsed or refractory diffuse large B-cell lymphoma after at least 2 therapies Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Xevinapant with platinum-based chemoradiotherapy for previously untreated locally advanced squamous cell carcinoma of the head and neck Xevinapant (Debio 1143; AT-406) Head and neck cancer Head and Neck Cancer 2022 View  |  Download
Xeomin for sialorrhea in children and adolescents aged 2 to 17 years Botulinum toxin A (Dysport; AbobotulinumtoxinA; Xeomin; Incobotulinumtoxin A; ANT-1207; Botox; OnabotulinumtoxinA; RT002; Daxibotulinumtoxin A; Azzalure; RT-001; NT 201; AGN-151607) Sialorrhea Dental and Oral Health 2020 View  |  Download
Xeomin (Botulinum neurotoxin type A) for lower limb and/or upper limb spasticity Botulinum toxin A (Dysport; AbobotulinumtoxinA; Xeomin; Incobotulinumtoxin A; ANT-1207; Botox; OnabotulinumtoxinA; RT002; Daxibotulinumtoxin A; Azzalure; RT-001; NT 201; AGN-151607) Lower limb spasticity , Upper limb spasticity Musculoskeletal System 2023 View  |  Download
WP1048 for treating grass pollen allergy WP1048 Grass pollen allergy Ear Nose and Throat (ENT) , Immunology 2023 View  |  Download
VX-659/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 years and older Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) , VX-659 (Bamocaftor-potassium) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
VX-659/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 12 years and older Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) , VX-659 (Bamocaftor-potassium) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
VX-445/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 years and older Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications